Boehringer, Envisagenics to develop precision cancer therapies

Boehringer, Envisagenics to develop precision cancer therapies

Under the agreement, Envisagenics is set to receive more than $1bn through potential payments. These include an upfront sum, research funding, option fees, and milestones related to commercialisation, The post Boehringer and Envisagenics to develop precision cancer therapies appeared first on Pharmaceutical Business review.

Boehringer and Envisagenics to develop precision cancer therapies

Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid tumours.